Karyopharm Therapeutics Inc. reiterated revenue guidance for the full year 2023. For the year, the company expected total revenue to be in the range of $145 million to $160 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.